RxDoctor Payments Data

Louis Williams, MD

Hematology & Oncology · Cleveland, OHNPI 1467839860

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $22,110 of the $33,538 with a category attached, or 65.9%. 12 manufacturers reported payments, led by Johnson & Johnson at 49.2% of the total. 2025 is the largest year on record at $12,752, more than ten times the $152 reported in 2021.

$33,538in general payments, 2019–2025

Across 54 payments — averaging $621.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$16K
  • E.r. Squibb & Sons, L.L.C.$12K
  • Legend Biotech USA Inc.$3K
  • Sanofi$737
  • Janssen Scientific Affairs, LLC$440
  • Regeneron Healthcare Solutions, Inc.$144
  • plus $557 from 6 others
$809,402in research payments, 2019–2025

Across 72 payments — averaging $11,242 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$736K
  • AbbVie$38K
  • Janssen Research & Development, LLC$36K

What the payments were for

  • Consulting fees$22,11066%
  • Grants$5752%
  • Travel & lodging$2,4657%
  • Food & beverage$2,2907%
  • Education$6,09818%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,538 in reported general payments places this provider in the 85th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$55,293
Medicare patients
116
Services billed
642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide32$599,348
Lenalidomide41$510,266
PomalystPomalidomide22$472,093
BrukinsaZanubrutinib29$418,032
EliquisApixaban29$15,971
Acyclovir145$2,053
ValacyclovirValacyclovir Hcl16$1,647
Prochlorperazine Maleate11$215
Potassium Chloride11$98
Prednisone13$72
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim21$65
Cyclobenzaprine Hcl12$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$11,833$472,09322 claims
Beigene USA, Inc.Brukinsa$139$418,03229 claims
PfizerEliquis$99$15,97129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →